4/A: Pfizer SVP & Controller Jennifer B. Damico Reports Share Withholding for Tax Obligations

Jennifer B. Damico, SVP & Controller at Pfizer Inc., reported the withholding of 377 common stock shares to cover tax obligations upon the vesting of restricted stock units on February 24, 2025.

Summary

• On February 24, 2025, Jennifer B. Damico, SVP & Controller of Pfizer Inc., reported a transaction involving the withholding of 377 common stock shares.
• The shares were withheld to satisfy tax obligations related to the vesting of restricted stock units.
• Following the transaction, Damico directly owns 8,647 shares of Pfizer common stock.
• The transaction was reported on Form 4/A, an amendment to a previous filing on February 25, 2025.
• Damico has a power of attorney in place, authorizing Tara J. Gabbai, Lori P. Hernando, Esther H. Louis, Margaret M. Madden, Madelyn D. Purcell, Shanice A. Reid and Anika Reynolds to act on her behalf for Section 16 filings.

Sentiment

Score: 5

Explanation: This is a neutral filing related to standard insider trading reporting requirements. It doesn't indicate positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider transactions and is a normal part of corporate governance for publicly traded companies like Pfizer.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders at publicly traded companies, such as Pfizer, and are comparable to similar filings made by executives at companies like Johnson & Johnson (JNJ) or Merck (MRK).
• The reporting requirements are governed by Section 16 of the Securities Exchange Act of 1934.
• The volume of shares withheld is relatively small, suggesting a routine tax obligation rather than a significant change in the executive's holdings.

Key Dates